Rx&D Welcomes Novo Nordisk Canada Inc. as its Newest Member

Rx&D Welcomes Novo Nordisk Canada Inc. as its Newest Member 
OTTAWA, ONTARIO -- (Marketwire) -- 03/01/13 -- Canada's
Research-Based Pharmaceutical Companies (Rx&D) is pleased to announce
that Novo Nordisk Canada Inc. has joined the association, which
represents the innovative pharmaceutical industry in Canada. 
"More and more companies are recognizing the value of Rx&D
membership, which includes our Code of Ethical Practices and our
patient-focused, collaborative approach to developing sustainable
healthcare solutions for Canada. We are pleased to welcome Novo
Nordisk and their expertise which gives us a broader foundation,
making the research-based pharmaceutical industry even stronger,"
said Rx&D President Russell Williams.  
"At Novo Nordisk, we are committed to helping Canadians achieve the
best health outcomes. Ninety years ago our Danish founders began a
journey to change diabetes. Today, our passion is providing
innovations to patients around the world"," said Vince Lamanna,
President, Novo Nordisk Canada. "We look forward to working with Rx&D
in the months and years ahead to ensure our industry is able to bring
the best possible care to Canadians.  
About Rx&D  
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our
community represents the men and women working for more than 50
member companies which invest more than $1 billion in research and
development each year to fuel Canada's knowledge-based economy,
contributing over $3 billion to the Canadian economy. Guided by our
Code of Ethical Practices, our membership is committed to working in
partnership with governments, private payers, healthcare
professionals and stakeholders in a highly ethical manner.  
About Novo Nordisk Canada Inc.  
Novo Nordisk is a healthcare company and a world leader in diabetes
care and biopharmaceuticals. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. Novo
Nordisk's business is driven by the Triple Bottom Line: a commitment
to economic success, environmental soundness, and social
responsibility to employees and customers. For more information,
visit www.novonordisk.ca.
Contacts:
Isabelle Robillard
Director, Media Relations
613-236-0455 extension 831
irobillard@canadapharma.org